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Abstract
Background:  The hospital treatment of heart failure frequently does not follow published
guidelines, potentially contributing to the high morbidity, mortality and economic cost of this
disorder. Consequently the development of clinical pathways has the potential to reduce the
current variability in care, enhance guideline adherence, and improve outcomes for patients.
Despite enthusiasm and diffusion, the widespread acceptance of clinical pathways remain
questionable because very little prospective controlled data demonstrated their effectiveness. The
Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of
Clinical Pathways was designed in order to conduct a rigorous evaluation of clinical pathways in
hospital treatment of acute heart failure. The primary objective of the trial was to evaluate the
effectiveness of the implementation of clinical pathways for hospital treatment of heart failure in
Italian hospitals.
Methods/design: Two-arm, cluster-randomized trial. 14 community hospitals were randomized
either to arm 1 (clinical pathway: appropriate use of practice guidelines and supplies of drugs and
ancillary services, new organization and procedures, patient education, etc.) or to arm 2 (no
intervention, usual care). 424 patients sample (212 in each group), 80% of power at the 5%
significance level (two-sided). The primary outcome measure is in-hospital mortality. We will also
analyze the impact of the clinical pathways comparing the length and the appropriateness of the
stay, the rate of unscheduled readmissions, the customers' satisfaction and the costs treating the
patients with the pathways and with the current practice along all the observation period. The
quality of the care will be assessed by monitoring the use of diagnostic and therapeutic procedures
during hospital stay and by measuring key quality indicators at discharge.
Discussion: This paper examines the design of the evaluation of a complex intervention. Since
clinical pathways are made up of various interconnecting parts we have chosen the cluster-
randomized controlled trial because is widely accepted as the most reliable method of determining
effectiveness when measuring cost-effectiveness in real practice.
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Background
In Europe approximately 5% of all acute medical admis-
sions relate to heart failure and in the United States heart
failure is responsible for almost 1 million hospitalizations
annually. Almost three quarters of these admissions are
unplanned and worsening heart failure is responsible for
half of these admissions [1,2].
The Acute Decompensated Heart Failure National Registry
(ADHERE) showed that the hospital treatment of heart
failure frequently does not follow published guidelines or
conform to the Joint Commission on Accreditation of
Healthcare Organizations (JCAHO) core performance
measures, potentially contributing to the high morbidity,
mortality and economic cost of this disorder [3,4].
ADHERE findings also suggested that the wide variations
in conformity may reflect differences in training, guide-
line familiarity, and implementation of tools and systems
to ensure that recommended care is provided and docu-
mented. Consequently the development of educational
and quality improvement programs has the potential to
considerably reduce the current variability in care,
enhance guideline adherence, and improve outcomes for
patients [5].
Clinical pathways has become a popular tool to achieve
such goals [6-8]. Clinical pathways are a methodology for
the mutual decision making and organization of care for
a well-defined group of patients during a well-defined
period with the aim to enhance the quality of care by
improving patient outcomes, promoting patient safety,
increasing patient satisfaction, and optimizing the use of
resources. They are also developed by multi-professional
teams [9]. Despite enthusiasm and diffusion, the wide-
spread acceptance of clinical pathways remain questiona-
ble because very little prospective controlled data
demonstrated their effectiveness [10-12].
The Experimental Prospective Study on the Effectiveness
and Efficiency of the Implementation of Clinical Path-
ways was designed in order to conduct a rigorous evalua-
tion of clinical pathways in hospital treatment of
decompensated heart failure.
Objectives
The primary objective of the trial was to evaluate the effec-
tiveness of the implementation of clinical pathways for
hospital treatment of heart failure among a sample of Ital-
ian hospitals. Our hypothesis was that the clinical path-
ways should be more effective than usual care in treating
patients admitted in hospital for heart failure and that the
clinical pathways should reduce patients' mortality during
the stay and that they should improve patients' outcomes
at discharge.
Secondary objectives were to estimate the efficiency and
the appropriateness of the use of the resources associated
with the intervention and its effects on other relevant out-
comes.
The third objective was to define a statistical model able
to predict in-hospital death and unscheduled re-admis-
sion.
A follow up study to evaluate the effectiveness of the inter-
vention after three years from baseline was described in a
separate protocol.
Methods/Design
The Project
The Experimental Prospective Study on the Effectiveness
and Efficiency of the Implementation of Clinical Path-
ways was promoted and funded by the Italian Ministry of
Health (Special Programs art. 12 bis D.lgs 229/99) and
Marche Region. The study's Steering Committee defined
the study's objectives, clinical topics, scheduling and
design. The Regional Healthcare Agency of Marche Region
coordinated and gave administrative support to the
project and handled patients' data according to the Italian
Data Protection act.
Study design
We performed a cluster multi-centre randomized control-
led clinical trial to evaluate the effect of applying clinical
pathways to process and outcome indicators and to the
costs sustained to assist the patients with heart failure. We
compared the results obtained treating the patients with
clinical pathways to the results obtained with the usual
care. Since a clinical pathway is not a single intervention
to be compared with a placebo but its eventual benefits
come from a mix of complex actions that are imple-
mented at the institutional level (appropriate use of prac-
tice guidelines and supplies of drugs and ancillary
services, new organization and procedures, patient educa-
tion, etc.), we randomly assigned hospitals, rather than
individual patients, to either introduce the pathway or
continue usual care [13-17].
Forty hospitals based in four Italian Regions were invited
to participate to the study (Figure 1). Eighteen hospitals
showed interest in the implementation of the clinical
pathway for the hospital treatment of heart failure and
were assessed for eligibility. Of the eighteen hospitals that
asked to implement the clinical pathway for heart failure
we selected and randomized fourteen community hospi-
tals. We based the selection on the comparability of their
location, patient population, facilities and teaching status
(mean bed size of the hospitals assigned to clinical path-
ways was 245, in the usual care group was 262).BMC Health Services Research 2007, 7:179 http://www.biomedcentral.com/1472-6963/7/179
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One hospital was excluded because it did not match with
the inclusion criteria (it was a national institute special-
ized in geriatric hospital care and research) and one hos-
pital withdrew after the project kick off meeting on a
decision of the hospital management. To participate to
the study the administrations of the hospitals had to be
allow the institution to be allocated to either of the two
strategies (clinical pathway or current practice) for a 1-
year period and to agree not to implement a clinical path-
way for the treatment of heart failure if assigned to the
usual care group. Two hospitals could not assure do not
implement a pathway if assigned to the control group and
therefore were not sampled.
Study evaluations
The primary outcome measure is in-hospital mortality.
We will also analyze the impact of the clinical pathways
comparing the length and the appropriateness of the stay,
the rate of unscheduled readmissions, the customers' sat-
isfaction and the costs treating the patients with the path-
ways and with the current practice along all the
observation period. The quality of the care will be assessed
by monitoring the use of diagnostic and therapeutic pro-
cedures during hospital stay and by the use of key quality
indicators at discharge, as reported in previous studies
[18-22]. The list of process and outcome indicators is
reported in Table 1.
Study sample
The sample included all the patients treated by the hospi-
tals during the experimental period with a principal diag-
nosis of heart failure (all ICD-9CM codes included in
428.xx code). We calculated the sample size needed to
detect a statistical difference in the mortality rate. Since in
Italy the in-hospital mortality rates range from 5% to
17%, we expected that clinical pathways succeeded to
control mortality to 5% to be clinically relevant [23-25].
Based on this goal a sample size of 424 patients (212 in
each group) was required for the study to have 80% power
at the 5% significance level (two-sided). The sample size
Flow diagram of the progress of the units through the trial Figure 1
Flow diagram of the progress of the units through the trial.
Hospitals invited 
to participate (n=40)
Hospitals assessed for 
eligibility (n=18)
Hospitals randomized
(n=14)
Excluded (n=4)
Not meeting inclusion 
criteria (n=1)
Withdraw after project 
kick off (n=1)
Accepted to participate 
but not sampled (n=2)
Hospitals that did not
consent to participate 
(n=22)
Hospitals enrolled to 
intervention (n=7)
Hospitals enrolled 
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calculation was performed according to standard criteria
for cluster randomized trials. We adjusted the sample size
using an inflation factor of 1.51 to account for the cluster
randomization: 7 clusters per trial arm, cluster size of 30
patients, ICC of 0.018 [26-29].
At baseline we verified the comparability of the two
groups at the admission measuring patients' age, sex, co-
morbidities, risk factors and symptoms severity (Table 2).
Patients with a current AMI or unstable angina were
excluded from the study.
Intervention
The project started at each hospital with a ground round
that showed the project protocol. Each hospital was
assigned one methodological leader by the study Steering
Committee (physicians or nurses with at least a two years
experience with clinical pathways) that assisted local
multidisciplinary teams in the development of the path-
ways and in the project implementation. The composition
of each team was different in each institution and
included general hospital-based physicians, cardiologists,
epidemiologists, pathologists, psychologists, nurses, hos-
pital-based pharmacists, social workers and administra-
tive peoples. The teams were formed on a voluntary base,
received a 3 days training in the development of clinical
pathways and constructed the clinical pathways over a 6-
month period.
The teams analyzed their care processes, did research for
the best evidences and defined the appropriate goals to
satisfy the multidimensional needs of the patients. These
results were detailed into protocols and documentation,
including the sequence of events and expected progress of
the patients over time. The tasks for each professional
were defined according to the following care categories:
patients' evaluation; education of patients and families;
planning of discharge; diagnostic exams; interventions
and procedures; consultancies; medical treatments; nutri-
tion; patients' safety [6,11].
Table 1: The indicator set.
Indicator (measure) Typology Criterion met/expected change Measure
In hospital mortality Outcome Differences in rates %
Length of hospital stay Outcome Differences in mean values days
Appropriateness of the stay (with Appropriateness Evaluation Protocol – 
AEP)
Outcome Differences in rates %
Costs of the stay (with Activity Based Costing – ABC) Outcome Differences in mean values € (euro)
Rate of unscheduled readmissions (within 31 days) Outcome Differences in rates %
Patients' satisfaction (survey with 16 items questionnaire) Outcome Differences in mean values score (1–10)
Diagnostic procedures during hospital stay Process Differences in rates %
Echocardiography
Trans-oesophageal echocardiography
Electrocardiography
Chest x-rays
Oximetry
Weight monitoring
Diuresis monitoring
Medical treatment during hospital stay Process Differences in rates %
Inotropes
ACE-inhibitors
Beta-blockers
Diuretics
Nitrates
Other vasodilators
Heparin
Oral anticoagulants
Anti-platelets agents
Left ventricular function (LVF) assessment rate at discharge (or planned for 
after discharge)
Process Given to all patients %
Rehabilitation rate at discharge (or planned for after discharge) Process Given to all patients %
Advice/counseling rate for smoking cessation at discharge Process Given to all patients (current smokers) %
Written instructions rate at discharge (activity level, diet, discharge 
medications, follow up, weight monitoring and what to do if symptoms 
worsen)
Process Given to all patients %
ACE-inhibitor rate at discharge (without contraindications, with LVF < 40%) Process Given to all patients %BMC Health Services Research 2007, 7:179 http://www.biomedcentral.com/1472-6963/7/179
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The clinical pathways were analyzed by the EBM unit of
the Regional Healthcare Agency of Marche and they were
judged consistent with current recommendations for the
diagnosis and the treatment of heart failure. After the val-
idation of the pathways each team educated in its hospital
the staff to the use of the clinical pathway and monitored
the use of the pathway.
Data analysis
Data were prospectively collected by local staff both in
intervention and in control groups (physician and nurses
who were trained in two pre-study educational events).
We did not use incentives for the local staff.
The analysis will be performed by the research team. In
addition to common descriptive statistics (Fisher exact
and Kruskal Wallis test for categorical and continuous var-
iables, respectively), that will be performed at the cluster
level, the differences in the rate of in-hospital deaths and
unscheduled admissions across groups and according to
each variable under study will be evaluated using random-
effects logistic regression, thus accounting for the cluster-
ing effect [30-33]. Variables will be included if significant
at the 0.10 level (backward approach), with the exception
of age which will be forced to entry. The presence of mul-
ticollinearity, interaction and higher power terms will be
assessed to check final model validity. Patients who died
during the study will be excluded from the regression
model evaluating unscheduled readmissions because they
could not be re-admitted.
Statistical significance will be defined as a two-sided p-
value < 0.05. All analyses will be intention-to-treat and
will be carried out using STATA statistical software, ver-
sion 8.2 (Stata Corporation, College Station, Texas,
2003).
Ethics
The project was exempt from ethical clearance according
to the Italian Ministry of Health law number (ex art. 12bis
D.lgs 229/99). Moreover the aim of the study is to
improve quality of care through clinical pathways and
thus should not imply any risk for the patients affected by
the study. It is difficult to imagine that our intervention
based on better evidences and appropriate use of technol-
ogies and drugs could worsen the quality of care when
compared to usual care. So according to other experiences
dealing with clinical pathways or implementation of evi-
dence based guidelines in practice we think that a Com-
mittee of Research Ethic would not consider it necessary
to submit the protocol for approval [34,35].
Discussion
Even though randomized controlled trials are widely
accepted as the most reliable method of determining
effectiveness, clinical pathways has not been studied suffi-
ciently in this way. Typically controlled trial design is not
used in evaluating clinical pathways because the context
level adaptation, which is essential for pathways to work,
is perceived as inappropriate in the trial design, likely for
the difficulty of keeping replicable and recognizable the
intervention [36]. According to Hawe we think that a con-
trolled trial design is appropriate to evaluate clinical path-
ways as well as other complex interventions and that it is
possible to standardize the intervention (the clinical path-
ways) effectively. To this purpose we defined as standard
the steps in the change process or the key functions that
the elements of the intervention were meant to improve
according to each context. Also the definition of the qual-
ity care indicators helped. The indicators were driven by
the theory and concerned the functions provided by the
key elements of the intervention that were based on
expected adherence to the same evidences. We think that
Table 2: Characteristics of 429 Hospital Patients in the Clinical Pathway and Usual Care Study Groups (demographics, risk factors and 
disease severity at admission).
Variable Clinical pathway (n = 214) Usual Care (n = 215) p value
Male gender 102 110 0.50
Mean age in years (SD) 81.7 (8.3) 79.6 (8.5) 0.011
Admitted from
General practitioner 106 109 0.77
Home 108 106
Severity at admission
NYHA II 16 15
NYHA III 117 114 0.87
NYHA IV 81 86
Co morbidities
Hypertension 154 161 0.58
COPD 52 58 0.58
Diabetes 41 38 0.71
Smoking 34 31 0.68BMC Health Services Research 2007, 7:179 http://www.biomedcentral.com/1472-6963/7/179
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this strategy based on combining local change standards
to the use of shared evidence based indicators kept the
integrity of the intervention in each site.
Since clinical pathways are made up of various intercon-
necting parts we have chosen the cluster-randomized con-
trolled trial design because is widely accepted as the most
reliable method of determining effectiveness in Health
Services Research [37]. As reported in sample size litera-
ture in cluster-randomized controlled trial we had diffi-
culties in defining the sample size for the dual nature of
the trial that focused both on individuals and clusters. The
sample size calculation was based on the number of indi-
viduals needed, while the randomization process was
based on clusters. Since each additional cluster repre-
sented a large proportionate increase in the study size
(and in associated costs) it was necessary to find the
proper balance between the need to increase the number
of the clusters and its organizational costs. According to
cluster design the sample size calculation needed to pre-
dict not only the expected effect size, but also the antici-
pated cluster size and ICC and this was difficult because
the lack of published data on clinical pathways. However
we think that the number of clusters and of individuals
included in our sample assured the viability of the trial
[27,29,37,38].
We had further difficulties related to current Italian
healthcare information systems, above all in the method
of documenting and collecting data from current sources
(clinical records, paper based abstraction tools, etc.). We
think that with a more comprehensive information struc-
ture for the clinical pathways, data collection would be
easier even though the actual process did not affect the
quality of the data but only reduced the efficiency of its
collection.
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